Edition:
United States

Novan Inc (NOVN.OQ)

NOVN.OQ on NASDAQ Stock Exchange Global Market

3.03USD
23 May 2018
Change (% chg)

$-0.02 (-0.66%)
Prev Close
$3.05
Open
$3.03
Day's High
$3.11
Day's Low
$3.02
Volume
1,404
Avg. Vol
12,751
52-wk High
$7.30
52-wk Low
$2.65

Latest Key Developments (Source: Significant Developments)

Reedy Creek Investments Reports 26.4 Percent Stake In Novan Inc
Monday, 22 Jan 2018 12:26pm EST 

Jan 22 (Reuters) - REEDY CREEK INVESTMENTS ::REEDY CREEK INVESTMENTS LLC REPORTS 26.4 PERCENT STAKE IN NOVAN INC AS OF JANUARY 9 - SEC FILING.  Full Article

Novan Says Interim CFO William Hodges To Step Down
Friday, 19 Jan 2018 05:38pm EST 

Jan 19 (Reuters) - Novan Inc ::NOVAN INC - WILLIAM L. HODGES, INTERIM CHIEF FINANCIAL OFFICER NOTIFIED THE CO OF HIS DECISION TO STEP DOWN EFFECTIVE JANUARY 19, 2018.NOVAN SAYS ‍EXPECTS TO HIRE A PERMANENT CHIEF FINANCIAL OFFICER IN FIRST HALF OF 2018 - SEC FILING​.  Full Article

Novan Announces Pricing Of $38.0 Mln Offering Of Common Stock And Warrants
Friday, 5 Jan 2018 09:00am EST 

Jan 5 (Reuters) - Novan Inc ::NOVAN ANNOUNCES PRICING OF $38.0 MILLION OFFERING OF COMMON STOCK AND WARRANTS.NOVAN- PRICING OF OFFERING OF 10 MILLION SHARES OF COMMON STOCK, WARRANTS TO BUY UP TO 10 MILLION SHARES OF COMMON STOCK WITH AN EXERCISE PRICE OF $4.66.NOVAN INC - SHARES AND WARRANTS ARE BEING SOLD AT A PUBLIC OFFERING PRICE OF $3.80 PER SHARE AND ACCOMPANYING WARRANT.  Full Article

Novan Announces Proposed Public Offering Of Common Stock And Warrants
Thursday, 4 Jan 2018 04:07pm EST 

Jan 4 (Reuters) - Novan Inc ::NOVAN ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK AND WARRANTS.  Full Article

Novan announces first patient dosed in phase 1B Atopic Dermatitis trial With Sb414
Tuesday, 5 Dec 2017 08:35am EST 

Dec 5 (Reuters) - Novan Inc ::NOVAN ANNOUNCES FIRST PATIENT DOSED IN PHASE 1B ATOPIC DERMATITIS TRIAL WITH SB414.NOVAN INC - ‍ TOP LINE RESULTS FROM PHASE 1B ATOPIC DERMATITIS TRIAL WITH SB414​ ARE TARGETED FOR Q3 OF 2018.NOVAN INC - ‍TOP LINE RESULTS ARE TARGETED FOR Q2 OF 2018 FROM PREVIOUSLY ANNOUNCED PHASE 1B CLINICAL TRIAL WITH SB414 FOR TREATMENT OF PSORIASIS​.  Full Article

Novan says ‍agreed to business structure to enable development of SB204 via 3rd party financing and execution
Tuesday, 7 Nov 2017 08:05am EST 

Nov 7 (Reuters) - Novan Inc ::Novan Inc -‍agreed to business structure to enable development of SB204 via 3rd party financing, 3rd party execution of additional Phase 3 pivotal trial​.Novan Inc - ‍proposed Phase 3 trial would be executed by third party's dermatology drug development team​.Novan Inc - a ‍new entity established by third party to provide capital to fund, expertise to execute additional Phase 3 pivotal trial for sb204​.  Full Article

Novan acquires IP rights to treat viral malignancies with nitric oxide
Wednesday, 18 Oct 2017 07:05am EDT 

Oct 18 (Reuters) - Novan Inc :Novan acquires IP rights to treat viral malignancies with nitric oxide.Novan Inc- ‍ Has initiated clinical development of company's nitric oxide platform in field of immunology​.Novan Inc- ‍Top line results for phase 1b trial of co's nitric oxide platform​ are expected in Q2 of 2018.Novan Inc- ‍Targeting to begin phase 1b trial with SB414 in adults with atopic dermatitis before year end with top line results expected in Q3 of 2018​.  Full Article

BRIEF-Novan Provides Update On SB414 Inflammatory Skin Disease Development Program

* NOVAN PROVIDES UPDATE ON SB414 INFLAMMATORY SKIN DISEASE DEVELOPMENT PROGRAM